The Cost Effectiveness of Tacrolimus versus Microemulsified Cyclosporin: A 10-Year Model of Renal Transplantation Outcomes

PharmacoEconomics

Volumn 21, Issue 17, 2003, Pages 1263-1276

  Orme, Michelle E ^a   Jurewicz, Wieslaw A ^b   Kumar, Nagappan ^b   McKechnie, Tracy L ^a  

^a Lewin Group   (United Kingdom)

^b CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG FORMULATION; FOLLOW UP; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MICROEMULSION; MONTE CARLO METHOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; COST SAVINGS; COST-BENEFIT ANALYSIS; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, ECONOMIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; TACROLIMUS; TREATMENT OUTCOME;

EID: 0346328317     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321170-00003     Document Type: Article

References (25)

1. Hutton J. The economics of immunosuppression in renal transplantation: a review of recent literature. Transplant Proc 1999; 31: 1328-32
2. Shield CF, McGrath MM, Gross TF. Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression: FK506 Kidney Transplant Study Group. Transplantation 1997; 64: 1738-43
3. Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant 1999; 13 (3): 209-20
4. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral) in organ transplantation. Drugs 2001; 61 (13): 1957-2016
5. Van Hoof JP, Christiaans MHL. Use of tacrolimus in renal transplantation. Transplantation Proc 1999; 31: 3298-9
6. Hauser IA, Neumayer HN. Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation: European Multicentre Tacrolimus (FK506) Renal Study Group. Transpl Int 1998; 11 Suppl. 1: S73-7
7. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64 (3): 436-43
8. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation: FK506 Kidney Transplant Study Group. Transplantation 1997; 63 (7): 977-83
9. McKenna M, Alexander G, Jones M, et al. Economic analysis of tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. EHP 1996; 2 (4): 181-8
10. Margreiter R. European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359 (9308): 741-6
11. Jurewicz WA. Tacrolimus versus ciclosporin immunosuppression: long-term outcome in renal transplantation. Nephrology Dialysis Transplantation 2003 May; 18 Suppl. 1: i7-11
12. Morris-Stiff G, Richards T, Singh J, et al. Pharmaco-economic study of FK 506 (Prograf) and Cyclosporine A al in cadaveric renal transplantation. Transplantation Proc 1998; 30: 1285-6
13. Jurewicz WA. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. Transplantation Proceedings 1999 Nov; 31 (7A): 64S-6S
14. Jurewicz WA, Kumar N, McKenna M, et al. An economic comparison of tacrolimus and cyclosporin microemulsion in kidney transplantation. 4th Annual Congress of British Transplantation Society. March 2001 27-29; Oxford
15. Chilcot J, Corcoran M, Rigg KM, et al. Tacrolimus and mycophenolate mofetil as maintenance immunosuppressants following renal transplantation. Guidance notes for purchasers: 99/07. UK: Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield, 1999
16. Morris PJ. Renal transplant audit: UKTSSA Users Kidney Advisory Group. UK: National Audit Office, 1995 Jun
17. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 1987
18. National Institute for Clinical Excellence. Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. London: National Institute for Clinical Excellence, 2001 Jun
19. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles and validity. Value Health 2001; 4 (5): 348-61
20. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000 May; 17 (5): 479-500
21. Tsuji-Hayashi Y, Fukuhara S, Green J, et al. Health-related quality of life among renal-transplant recipients in Japan. Transplantation 1999 Nov 15; 86 (9): 1331-5
22. Fujisawa M, Ichikawa Y, Yoshiya K, et al. Assessment of health-related quality of life in renal transplant and hemodialysis patients using the SF-36 health survey. Urology 2000 Aug 1; 56 (2): 201-6
23. Reimer J, Franke GH, Philipp T, et al. Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine-micro-emulsion. Clin Transplant 2002 Feb; 16 (1): 48-54
24. Rebollo P, Ortega P, Baltar JM, et al. Health-related quality of life (HRQOL) of kidney transplanted patients: variables that influence it. Clin Transplant 2000 Jun; 14 (3): 199-207
25. Booth-Clibborn N, Best L, Stein K. Tacrolimus after kidney transplantation: report to the Development and Evaluations Committee. Southampton: Wessex Institute, 1997 Sep. Report no. 74